Pancreatic and Lung cancer kill over 2 million people per year globally and results in billions in economic loss. Our solution is to detect cancer early to give patients the most options for treatment and survival.
When have secured significant interest from Mayo clinic physicians and researchers which has the potential to provide clinical samples needed to further substantiate the efficacy of our product. In addition, the ventures team has expressed willingness to work with us for investment by Mayo. On the ASU side, we have secured interest in having interns from the Regulatory Sciences program to help with coding, regulatory filings, and clinical business system design and implementation.
"The MedTech Accelerator program provided a comprehensively structured curriculum, environment, and resource set to truly facilitate the success of PharusDx."
Scott Taylor
Head of Commercial, Pharus DX